MACROGENICS INC (MGNX) — SEC Filings

Latest SEC filings for MACROGENICS INC (MGNX), explained in plain English.

Sentiment Overview: 2 bullish, 2 bearish, 31 neutral

Recent Filings (35)

• MacroGenics' Tebotelimab Study Meets Primary Endpoint — 8-K · 2026-04-08T16:41:59-04:00 [bullish] Risk: medium
  On April 8, 2026, MacroGenics Inc. filed an 8-K report detailing the results of the Phase 2 LINGO-2 study for its drug tebotelimab. The study met its primary en
• Macrogenics Files DEFA14A Proxy Materials — DEFA14A · 2026-04-08T16:02:26-04:00 [neutral] Risk: low
  Macrogenics Inc. filed a Definitive Additional Materials (DEFA14A) on April 8, 2026, related to proxy solicitations. The filing includes notice pages and a comp
• MacroGenics Appoints New Director — 8-K · 2025-11-20T00:00:00.000Z [neutral] Risk: low
  On November 14, 2025, MacroGenics, Inc. reported a change in its board of directors. Specifically, Dr. Scott R. Vandenberg has been appointed as a Class II Dire
• Macrogenics' Q3 Profit Plunges Amid Revenue Decline, Cash Burn Accelerates — 10-Q · 2025-11-12T00:00:00.000Z [bearish] Risk: high
  MACROGENICS INC reported a net income of $16.822 million for the three months ended September 30, 2025, a significant decrease from $56.309 million in the same
• MacroGenics Files 8-K Report — 8-K · 2025-08-14T00:00:00.000Z [neutral] Risk: low
  On August 14, 2025, MacroGenics, Inc. filed an 8-K report. The filing primarily serves as a notification of the company's status and does not disclose specific
• MacroGenics Reports Director Changes and Executive Compensation Updates — 8-K · 2025-08-13T00:00:00.000Z [neutral] Risk: medium
  On August 13, 2025, MacroGenics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indica
• MacroGenics Files 8-K: Material Agreement, Other Events — 8-K · 2025-06-10T00:00:00.000Z [neutral] Risk: medium
  On June 9, 2025, MacroGenics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial statements
• MacroGenics Files 8-K on Security Holder Vote Matters — 8-K · 2025-05-22T00:00:00.000Z [neutral] Risk: low
  On May 21, 2025, MacroGenics, Inc. filed an 8-K report indicating a submission of matters to a vote of security holders. The company, incorporated in Delaware w
• MacroGenics Q1 2025 Update: Revenue Streams Detailed — 10-Q · 2025-05-13T00:00:00.000Z [neutral] Risk: medium
  MacroGenics Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's financial filings indicate revenue from collaborati
• MacroGenics Files DEF 14A: Executive Compensation Details — DEF 14A · 2025-04-11T00:00:00.000Z [neutral] Risk: low
  MacroGenics Inc. filed a DEF 14A on April 11, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending December 31, 20
• MacroGenics Inc. Files 2024 10-K — 10-K · 2025-03-20T00:00:00.000Z [neutral] Risk: medium
  MacroGenics Inc. filed its 2024 10-K on March 20, 2025, reporting its fiscal year results ending December 31, 2024. The company, based in Rockville, MD, operate
• MacroGenics Files 8-K: Board and Executive Compensation Changes — 8-K · 2025-02-26T00:00:00.000Z [neutral] Risk: medium
  On February 25, 2025, MacroGenics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indi
• MacroGenics Appoints New Director — 8-K · 2024-11-21T00:00:00.000Z [neutral] Risk: low
  On November 18, 2024, MacroGenics, Inc. reported a change in its board of directors. Dr. Scott M. Freeman was appointed as a Class II Director, effective immedi
• SC 13G Filing — SC 13G · 2024-11-20T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-08T00:00:00.000Z [neutral]
• MacroGenics Q3 Revenue Surges to $36.6M — 10-Q · 2024-11-05T00:00:00.000Z [bullish] Risk: medium
  MacroGenics Inc. reported its third-quarter 2024 results, with total revenue for the three months ended September 30, 2024, reaching $36.6 million. This represe
• MacroGenics Announces CMO Departure and Appointment — 8-K · 2024-10-30T00:00:00.000Z [neutral] Risk: medium
  On October 25, 2024, MacroGenics, Inc. filed an 8-K report detailing several key events. The company announced the departure of Dr. Scott R. Lippman as Chief Me
• SC 13G/A Filing — SC 13G/A · 2024-10-22T00:00:00.000Z [neutral]
• MacroGenics Terminates Henlius Biotech Deal — 8-K · 2024-09-16T00:00:00.000Z [neutral] Risk: medium
  On September 16, 2024, MacroGenics, Inc. (MGNX) filed an 8-K report to announce the termination of its collaboration and license agreement with Shanghai Henlius
• MacroGenics Q2 Revenue Declines to $35.7M — 10-Q · 2024-08-06T00:00:00.000Z [bearish] Risk: medium
  MacroGenics Inc. reported its Q2 2024 results, with total revenue for the three months ended June 30, 2024, reaching $35.7 million, a decrease from $42.5 millio
• MacroGenics Appoints New Chief Medical Officer — 8-K · 2024-07-30T00:00:00.000Z [neutral] Risk: medium
  On July 24, 2024, MacroGenics, Inc. announced the appointment of Dr. Scott R. Vandenberg as its new Chief Medical Officer. Dr. Vandenberg brings extensive exper
• SC 13G Filing — SC 13G · 2024-06-04T00:00:00.000Z [neutral]
• MacroGenics Files 8-K on Shareholder Vote Matters — 8-K · 2024-05-23T00:00:00.000Z [neutral] Risk: medium
  On May 21, 2024, MacroGenics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, incorporated in Delaware wi
• SC 13G Filing — SC 13G · 2024-05-21T00:00:00.000Z [neutral]
• Macrogenics Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-09T00:00:00.000Z [neutral] Risk: medium
  MACROGENICS INC (MGNX) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Macrogenics Inc. reported financial results for the first quarter ended Marc
• MacroGenics Announces Annual Meeting of Stockholders on May 21, 2024 — DEF 14A · 2024-04-08T00:00:00.000Z [neutral] Risk: low
  MACROGENICS INC (MGNX) filed a Proxy Statement (DEF 14A) with the SEC on April 8, 2024. MacroGenics, Inc. will hold its Annual Meeting of Stockholders on May 21
• MacroGenics Files 8-K Report — 8-K · 2024-04-03T00:00:00.000Z [neutral] Risk: low
  On April 3, 2024, MacroGenics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating update
• Macrogenics Inc. Files 2023 Annual Report on Form 10-K — 10-K · 2024-03-07T00:00:00.000Z [neutral] Risk: medium
  MACROGENICS INC (MGNX) filed a Annual Report (10-K) with the SEC on March 7, 2024. Macrogenics Inc. filed its 10-K report for the fiscal year ending December 31
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• BlackRock Amends MACROGENICS Stake, Maintains Passive Position — SC 13G/A · 2024-01-24T00:00:00.000Z [neutral]
  BlackRock, Inc. filed an amended Schedule 13G/A on January 24, 2024, disclosing its ownership in MACROGENICS INC as of December 31, 2023. This amendment, the 9t